Between 2014 and 2017, a drug company raised the price of its opioid overdose treatment by more than 600 percent, a Senate investigation has found.
> The report from the Senate’s Permanent Subcommittee on Investigations finds that the company Kaléo raised the price of its drug EVZIO from $575 in 2014 to $4,100 in 2017.
> EVZIO is an auto-injector form of the drug naloxone, which is used to treat people overdosing on opioids, an occurrence that has reached crisis levels in the United States.
The report also said that the rise in pricing cost the government more than $142 million over the four-year period via charges to Medicare and Medicaid.
> “Kaléo’s more than 600 percent price increase of EVZIO not only exploits a country in the middle of an opioid crisis, but also American taxpayers who fund government-run health care programs designed to be a safety net for our country’s elderly and most vulnerable,” states the Senate report, which was led by Sens. Rob Portman (R-Ohio) and Tom Carper (D-Del.), the top lawmakers on the committee.
In a statement, the company said it has never turned a profit on the drug, adding that “Patients, not profits, have driven our actions.”
Kaléo also agreed that changes are needed and said it is working with “insurers, policymakers and government officials” to bring down the cost of EVZIO “while ensuring patients and their loved ones have access to this life-saving drug.”